Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 1,093 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 1,093 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was purchased at an average price of $23.86 per share, with a total value of $26,078.98. Following the purchase, the insider owned 651,114 shares of the company’s stock, valued at approximately $15,535,580.04. The trade was a 0.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc bought 17,763 shares of Surrozen stock. The shares were acquired at an average cost of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were acquired at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were bought at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were purchased at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Price Performance

SRZN traded down $0.36 during trading on Friday, hitting $24.48. The stock had a trading volume of 53,087 shares, compared to its average volume of 131,820. The company has a 50 day moving average price of $21.51 and a 200-day moving average price of $15.65. Surrozen, Inc. has a one year low of $5.90 and a one year high of $25.84. The firm has a market cap of $209.82 million, a price-to-earnings ratio of -1.10 and a beta of 0.58.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SRZN. Lifesci Capital raised Surrozen to a “strong-buy” rating in a report on Thursday, November 13th. Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Hedge Funds Weigh In On Surrozen

Large investors have recently modified their holdings of the business. Stempoint Capital LP lifted its holdings in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after purchasing an additional 445,713 shares during the period. Kalehua Capital Management LLC bought a new position in Surrozen during the 4th quarter worth $8,705,000. Stonepine Capital Management LLC raised its position in Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after buying an additional 47,468 shares during the period. Finally, Acuta Capital Partners LLC grew its position in shares of Surrozen by 5.0% in the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after buying an additional 8,415 shares during the last quarter. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.